Technical Documentation Requirements for Australian Medical Device Applications
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Australia has not directly incorporated Annexes II and III of the European MDR. The statutory obligation for technical documentation derives from Schedule 3 Part 1 clause 1.4(5) of the Therapeutic Goods (Medical Devices) Regulations 2002, and the alignment with the European Union is indirect — the TGA achieves it by accepting MDR Annex IX Chapter II or IVDR Annex IX technical documentation assessment certificates issued by European notified bodies. In other words, the bridge between the two regimes is built from assessment certificates rather than from any wholesale adoption of the European annexes, and the point of connection for every application is a specific item number in the Information Determination.
- Technical documentation sits inside the quality management system rather than being lodged as a standalone application file.
- Design examination under clause 1.6 applies only to Class III devices, Class 4 IVDs and Class 4 in-house IVDs, and clause 1.6(4) requires re-examination after substantial changes.
- For Class III, the column 4 alternative is a European MDR Annex IX Chapter II technical documentation assessment certificate (Schedule 1 Part 4 item 7, column 4).
- For IVDs, the corresponding route is technical documentation assessment under IVDR Annex IX clauses 4, 5.1 and 5.2 (Schedule 2 Part 2 item 5, column 4).
- The TGA’s IVD application audit guidance accepts the Essential Principles checklist, device description, risk management, stability, analytical performance and clinical evidence, as well as the IVDR list of general safety and performance requirements with a manufacturer declaration, and the IMDRF IVD table of contents structure.
2. Legal basis
Therapeutic Goods (Medical Devices) Regulations 2002 (F2002B00237, compilation F2026C00883, effective 8 September 2026): the technical documentation obligation appears in Schedule 3 Part 1 clause 1.4(5) — the quality management system must maintain technical documentation containing information on design, production and intended performance. The clause therefore treats the technical file as something the manufacturer holds and keeps current under the system, not as a package filed once with the regulator and archived afterwards.
Design examination: Schedule 3 Part 1 clause 1.6 (including clause 1.6(4), which requires re-examination after substantial changes). The applicable classes are only Class III devices, Class 4 IVDs and Class 4 in-house IVDs; design controls for all other classes are assessed through the quality management system audit rather than through a standalone design examination step.
The mode of alignment with the European Union runs through the Information Determination: Schedule 1 Part 4 item 7, column 4 (Class III: a European MDR Annex IX Chapter II technical documentation assessment certificate) and Schedule 2 Part 2 item 5, column 4 (IVDs: technical documentation assessment under European IVDR Annex IX clauses 4, 5.1 and 5.2).
Technical documentation review points in IVD application audits (TGA guidance Preparing for an application audit for in-vitro diagnostic medical devices, dated 12 May 2026): the TGA requires the Essential Principles checklist, device description, risk management, stability, analytical performance and clinical evidence; it expressly accepts the IVDR list of general safety and performance requirements accompanied by a manufacturer declaration; and the IMDRF IVD table of contents (ToC) structure may be used as a reference. Taken together, these points tell applicants what the reviewer will look for first and in what order, so the documentation should be arranged so that each of those elements can be found without searching.
3. Expert insights
Insight 1: technical documentation in Australia is a system document, not an application document. Clause 1.4(5) places technical documentation inside the quality management system requirement. This means it is maintained but not routinely lodged, and is retrieved during audits, inspections or disputes — a subtle difference from the European practice of keeping technical documentation ready for submission at any time. Teams that assume the European filing model will still reach the correct documents, but they may misjudge when and to whom the documents must be shown.
Insight 2: only the three high-risk classes undergo separate design examination. The design examination in clause 1.6 covers only Class III devices, Class 4 IVDs and Class 4 in-house IVDs. Design controls for lower-risk products are covered through the system audit, and no separate design examination evidence is required. Preparing design documentation for these classes to application-file standards will attract requests for supplementation at audit.
Insight 3: the IMDRF ToC is the common language of Australian audits. The TGA expressly allows the IMDRF IVD table of contents structure to be used as a reference in its IVD audit guidance. For companies filing in multiple jurisdictions, organising technical documentation according to the IMDRF ToC simultaneously serves Australia and several IMDRF member markets, so a single documented structure can be maintained once and reused across submissions without rebuilding the index for each regulator.
4. Practical recommendations
- Organise technical documentation according to the IMDRF ToC, and build a separate clause-to-document-location index covering the three categories of information in Schedule 3 Part 1 clause 1.4(5): design, production and intended performance.
- For Class III and Class 4 IVD projects, bind the design examination evidence into a separate volume, and reserve a re-examination process for substantial changes under clause 1.6(4).
- For projects using the European pathway, confirm that the certificate corresponds to Annex IX Chapter II (MDR) or Annex IX clauses 4, 5.1 and 5.2 (IVDR), and cite the item number in the application.
- Place the Essential Principles checklist at the front of the technical documentation so that auditors can locate the material quickly.
5. Verification checklist
- □ Technical documentation covers the design, production and intended performance information of clause 1.4(5)
- □ Documentation is organised per the IMDRF ToC with a clause index attached
- □ Design examination evidence under clause 1.6 is ready for the three high-risk classes
- □ European certificates have been confirmed against the specific Annex IX chapters
- □ The Essential Principles checklist is attached
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team prepares TGA-compliant CTOs and evidence dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us